全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Extensive Bi-Atrial Remodeling on Hypertensive Patient with Permanent Atrial Fibrillation Delayed Diagnosis of Fatal Cardiac Lambda Amyloidosis

DOI: 10.4236/wjcd.2024.146035, PP. 409-420

Keywords: Myeloma, Cardiac Lambda Light Chain Amyloidosis, Monoclonal Gammopathy, Heart Failure

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background: Amyloidosis is a disease characterized by the deposition of fibrillar proteins in tissues. The nature of the protein defines the type of amyloidosis. Cardiac involvement is most often secondary to deposits of transthyretin and immunoglobulin light chains. Treatment depends on the type of amyloidosis. Cardiac light chain amyloidosis is a medical emergency. Aim: To highlight the importance of an early diagnosis of cardiac light chain amyloidosis. Case Presentation: We report the case of an 88-year-old hypertensive female patient with sustained atrial fibrillation and recurrent heart failure, in whom echocardiography showed concentric left ventricle hypertrophy with mildly reduced left ventricle ejection fraction (LVEF) to 45%. Bone scintigraphy was normal. Serum analysis showed increased lambda free light chains. Accessory salivary gland biopsy revealed weak Kappa light chain staining and clear overexpression of lambda light chain deposits. The diagnosis of stage 3B cardiac amyloidosis secondary to lambda light chain myeloma was made. After a multidisciplinary meeting, it was decided to start treatment with DARATUMUMAB + LENALIDOMIDE. Patient’s general condition deteriorated with the occurrence of febrile pancytopenia. Chemotherapy was stopped and management was limited to comfort care until the patient’s death. Conclusion: Cardiac light-chain amyloidosis must be diagnosed early as it can be rapidly fatal.

References

[1]  Muchtar, E., Kumar, S.K., Gertz, M.A., Grogan, M., AbouEzzeddine, O.F., Jaffe, A.S., et al. (2019) Staging Systems Use for Risk Stratification of Systemic Amyloidosis in the Era of High-Sensitivity Troponin T Assay. Blood, 133, 763-766.
https://doi.org/10.1182/blood-2018-10-875252
[2]  Damy, T., Donal, E., Lairez, O., Eicher, J., Karoubi, M., Trochu, J., et al. (2024) Transthyretin Amyloid Cardiomyopathy in France: A Cross-Sectional Multi-Centre Study (333 Patients). Rare, 2, Article 100021.
https://doi.org/10.1016/j.rare.2024.100021
[3]  Damy, T., Bourel, G., Slama, M., Algalarrondo, V., Lairez, O., Fournier, P., et al. (2023) Incidence and Survival of Transthyretin Amyloid Cardiomyopathy from a French Nationwide Study of In-and Out-Patient Databases. Orphanet Journal of Rare Diseases, 18, Article No. 345.
https://doi.org/10.1186/s13023-023-02933-w
[4]  Nienhuis, H.L.A., Bijzet, J. and Hazenberg, B.P.C. (2016) The Prevalence and Management of Systemic Amyloidosis in Western Countries. Kidney Diseases, 2, 10-19.
https://doi.org/10.1159/000444206
[5]  Hou, H., Tang, C., Goh, C.H., Shen, S., Huang, K., Qiu, H., et al. (2022) A Population-Based Cohort Study of the Epidemiology of Light-Chain Amyloidosis in Taiwan. Scientific Reports, 12, Article No. 15736.
https://doi.org/10.1038/s41598-022-18990-3
[6]  Damy, T., Jaccard, A., Guellich, A., Lavergne, D., Galat, A., Deux, J., et al. (2016) Identification of Prognostic Markers in Transthyretin and AL Cardiac Amyloidosis. Amyloid, 23, 194-202.
https://doi.org/10.1080/13506129.2016.1221815
[7]  Fotiou, D., Dimopoulos, M.A. and Kastritis, E. (2020) Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management. HemaSphere, 4, e454.
https://doi.org/10.1097/hs9.0000000000000454
[8]  Wechalekar, A.D., Fontana, M., Quarta, C.C. and Liedtke, M. (2022) AL Amyloidosis for Cardiologists. JACC: CardioOncology, 4, 427-441.
https://doi.org/10.1016/j.jaccao.2022.08.009
[9]  Merlini, G., Dispenzieri, A., Sanchorawala, V., Schönland, S.O., Palladini, G., Hawkins, P.N., et al. (2018) Systemic Immunoglobulin Light Chain Amyloidosis. Nature Reviews Disease Primers, 4, Article No. 38.
https://doi.org/10.1038/s41572-018-0034-3
[10]  Damy, T., Zaroui, A. and Oghina, S. (2022) The Challenge of Managing Patients with Light-Chain Cardiac Amyloidosis: The Value of Cardiac Magnetic Resonance as a Guide to the Treatment Response. European Heart Journal, 43, 4736-4738.
https://doi.org/10.1093/eurheartj/ehac526
[11]  Quarta, C.C., Kruger, J.L. and Falk, R.H. (2012) Cardiac Amyloidosis. Circulation, 126, e178-e182.
https://doi.org/10.1161/circulationaha.111.069195
[12]  Oghina, S., Delbarre, M.A., Poullot, E., Belhadj, K., Fanen, P. and Damy, T. (2022) Les amyloses cardiaques: État des lieux en 2022. La Revue de Médecine Interne, 43, 537-544.
https://doi.org/10.1016/j.revmed.2022.04.036
[13]  Garcia-Pavia, P., Rapezzi, C., Adler, Y., Arad, M., Basso, C., Brucato, A., et al. (2021) Diagnosis and Treatment of Cardiac Amyloidosis: A Position Statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 42, 1554-1568.
https://doi.org/10.1093/eurheartj/ehab072
[14]  Dispenzieri, A., Gertz, M.A., Kyle, R.A., Lacy, M.Q., Burritt, M.F., Therneau, T.M., et al. (2004) Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis. Journal of Clinical Oncology, 22, 3751-3757.
https://doi.org/10.1200/jco.2004.03.029
[15]  Palladini, G., Sachchithanantham, S., Milani, P., Gillmore, J., Foli, A., Lachmann, H., et al. (2015) A European Collaborative Study of Cyclophosphamide, Bortezomib, and Dexamethasone in Upfront Treatment of Systemic AL Amyloidosis. Blood, 126, 612-615.
https://doi.org/10.1182/blood-2015-01-620302
[16]  Damy, T., Lairez, O., Algalarrondo, V. and Charron, P. (2020-2021) Protocole National de Diagnostic et de Soins (PNDS). Amyloses Cardiaques. Filière Cardiogen, Centre de référence Amyloses Cardia-ques.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133